Asthma

Overview

Despite a number of safe and effective therapies to treat asthma available, a high proportion of patients remain symptomatic and at risk for exacerbations. No standard PRO measure currently exists for asthma that is fit for measuring important patient-experienced aspects of the disease. Such a measure could be used in addition to measures like spirometric assessment of lung function in the development of drugs for the treatment of persistent asthma. The Asthma Working Group is developing the Asthma Daily Symptom Diary (ADSD) that will enable the capture of the core symptoms of asthma in adolescents and adults.

 

Presentations

icon-pdfIdentifying and Measuring the Core Symptoms Reported by Persons with Asthma: A review of the Existing Qualitative Literature and Patient-Reported Outcome Measures

Nelsen LM, Gater A, Hall R, Coons SJ, on behalf of the Patient-Reported Outcome Consortium’s Asthma Working Group. Identifying and Measuring the Core Symptoms Reported by Persons with Asthma: A review of the Existing Qualitative Literature and Patient-Reported Outcome Measures. American Thoracic Society (ATS) 2014 International Conference; 2014 May 16; San Diego, CA USA.

icon-pdfDevelopment of the Initial Version of the Asthma Daily Symptom Diary

Mocarski M, Gater A, Fleming S, Nelsen L, Coons S, on behalf of the Patient-Reported Outcome Consortium’s Asthma Working Group. Development of the Initial Version of the Asthma Daily Symptom Diary. American Thoracic Society (ATS) 2014 International Conference; 2014 May 16; San Diego, CA USA.

 

Working Group Sponsors

Allergan
AstraZeneca Pharmaceuticals LP
Boehringer Ingelheim Pharmaceuticals, Inc.
Genentech
GlaxoSmithKline
Janssen Pharmaceutical Companies of Johnson & Johnson
Merck, Sharp & Dohme Corp.
Novartis Pharmaceutical Corporation
Pfizer
Sanofi